PET PET
  • My Account
  • Subscribe
Become a Friend Donate
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • My Account
  • Subscribe
  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements
PETBioNewsNewsBig pharma investment in gene therapy continues with Sanofi deal

BioNews

Big pharma investment in gene therapy continues with Sanofi deal

Published 13 February 2015 posted in News and appears in BioNews 790

Author

Arit Udoh

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.

Sanofi has signed a partnership deal worth potentially US $845 million with Voyager Therapeutics, a comparatively small biotech firm, making it the latest major pharmaceutical firms to commit financially to gene therapy research...

Sanofi has signed a partnership deal worth potentially US $845 million with Voyager
Therapeutics
, a comparatively small biotech firm, becoming the latest in a series of major pharmaceutical firms to commit financially to gene therapy research.

According to a joint statement by the two companies, Genzyme, the Sanofi subsidiary involved in the deal, will work collaboratively with
Voyager Therapeutics to develop and ultimately commercialise 'novel
adeno-associated virus (AAV) gene therapies for Parkinson's disease, Friedreich’s ataxia, Huntington’s disease and other debilitating central
nervous system disorders.

Dr Steven
Paul
, president
and CEO of Voyager Therapeutics, says the alliance will ensure both companies
'are at the forefront of converting the promise of gene therapy into innovative
therapies for CNS disorders that make a meaningful difference in patients'
lives'.

According
to the agreement, Voyager Therapeutics will oversee research and development of
the specified gene therapy programmes, receiving an initial US $100 million upfront
payment from Genzyme, including US $65 million in cash.

Should
the programmes be successful and ultimately produce commercialised therapies,
Voyager Therapeutics could receive up to US $745 million in 'development and sales
milestones payments' and royalties.

Currently
Voyager has two products - in Parkinson's disease and Friedreich's ataxia - in early
clinical development, and others in preclinical trials.

Voyager
Therapeutics will retain the rights to the Parkinson's and Friedreich’s ataxia programmes
in the USA, and Genzyme will hold outside-US rights. The two companies plan to share
any eventual US profits from the project in Huntington's disease. Genzyme will have licensing options for
several other programmes after completion of proof-of-concept clinical trials.

Voyager's AAV gene
therapies involve silencing disease-causing gene mutations or replacing them with
healthy versions. The AAV viruses are used as vectors, delivering the repair genes to
the target.

According to industry
analysts FierceBiotech, the company is 'also
at work on new viral delivery vehicles that could mark a major improvement in
the field'.

In
the last year, three other important pharmaceutical players have
made similar collaborative deals with biotech firms to develop gene therapies.

Pfizer
(see BioNews 784), Biogen Idec (BioNews 788) and Bayer Healthcare's collaborations,
however, are all focused on haemophilia A and/or B.

Genzyme's
interest in gene therapy goes back over twenty years, enduring a fallow period
when the technique appeared to many too problematic to ever bear commercial
fruit. But last year Glybera, produced by the Dutch biotech UniQure, became the
first gene therapy product to go on sale in Europe (see BioNews 782).

'We really carried the torch for years when some other companies left
the space,' Mark Barrett, Genzyme's vice president of business development, told
FierceBiotech.

Related Articles

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
11 December 2017 • 2 minutes read

Gene therapy hope for haemophilia

by Charlotte Spicer

Scientists have successfully used gene therapy to prevent bleeding in a small trial of patients with the inherited blood disorder haemophilia B...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
8 May 2017 • 2 minutes read

Europe's first gene therapy withdrawn

by Kulraj Singh Bhangra

A million-dollar gene therapy treatment for a rare blood disease will be withdrawn from the European market due to lack of demand...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
30 January 2015 • 2 minutes read

Biogen makes moves in gene therapy

by Dr Lucy Freem

Biogen Idec has made an investment deal to develop gene therapy treatments for haemophilia A and B....

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
12 December 2014 • 2 minutes read

Pfizer to set up dedicated gene therapy development unit

by Seán Byrne

Pfizer has entered into a deal with biotech company Spark Therapeutics to conduct research into gene therapy for haemophilia B...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
28 November 2014 • 2 minutes read

World's first commercialised gene therapy set to be 'world's most expensive drug'

by Arit Udoh

Glybera, the first gene therapy to go on sale in Europe, is set to cost €1.1m (£870,000) per patient, making it the world's most expensive drug...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
23 November 2012 • 2 minutes read

Huntington's disease gene-silencing drug effective in animal studies

by Holly Rogers

A single dose of an 'antisense' drug has been shown to slow, or even partially reverse, Huntington's disease in animal studies, according to a study published in Neuron....

Leave a Reply Cancel reply

You must be logged in to post a comment.

« Is there a doctor in the house? New Jersey's artificial insemination law tested in custody battle

Data-Label The UK's Leading Supplier Of Medical Labels & Asset Labels

RetiringDentist.co.uk The UK's Leading M&A Company.
easyfundraising
amazon

This month in BioNews

  • Popular
  • Recent
13 June 2022 • 2 minutes read

Drop in diversity of blood stem cells leads to old-age health issues

6 July 2022 • 1 minute read

Frozen embryo transfers linked to high blood pressure in pregnancy

5 July 2022 • 1 minute read

Anorexia in pregnancy linked to increased risk of complications

5 July 2022 • 2 minutes read

Pregnancy after breast cancer treatment does not increase risk of recurrence

5 July 2022 • 1 minute read

No difference between fresh and frozen sperm for IUI

4 July 2022 • 2 minutes read

Shorter IVF protocol reduces risk of OHSS

Subscribe to BioNews and other PET updates for free.

Subscribe
  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856

Subscribe to BioNews and other PET updates for free.

Subscribe
PET PET

PET is an independent charity that improves choices for people affected by infertility and genetic conditions.

  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Navigation

  • About Us
  • Get Involved
  • Donate
  • BioNews
  • Events
  • Engagement
  • Jobs & Opportunities
  • Contact Us

BioNews

  • News
  • Comment
  • Reviews
  • Elsewhere
  • Topics
  • Glossary
  • Newsletters

Other

  • My Account
  • Subscribe

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856